Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.44
BIIB's Cash-to-Debt is ranked lower than
89% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. BIIB: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 3.89 Max: No Debt
Current: 0.44
Equity-to-Asset 0.53
BIIB's Equity-to-Asset is ranked lower than
65% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.77 Max: 0.96
Current: 0.53
0.48
0.96
Interest Coverage 17.60
BIIB's Interest Coverage is ranked lower than
81% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 17.60 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 17.6  Med: 42.88 Max: 134.66
Current: 17.6
17.6
134.66
Piotroski F-Score: 5
Altman Z-Score: 5.91
Beneish M-Score: -2.42
WACC vs ROIC
5.17%
23.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 38.72
BIIB's Operating Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. BIIB: 38.72 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 24.59  Med: 33.48 Max: 45.44
Current: 38.72
24.59
45.44
Net Margin % 28.10
BIIB's Net Margin % is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. BIIB: 28.10 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 28.1
19.11
32.95
ROE % 28.03
BIIB's ROE % is ranked higher than
96% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. BIIB: 28.03 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 10.06  Med: 20.75 Max: 35.15
Current: 28.03
10.06
35.15
ROA % 15.04
BIIB's ROA % is ranked higher than
94% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. BIIB: 15.04 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 7.43  Med: 14.4 Max: 22.42
Current: 15.04
7.43
22.42
ROC (Joel Greenblatt) % 124.41
BIIB's ROC (Joel Greenblatt) % is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. BIIB: 124.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.17  Med: 90.54 Max: 189.7
Current: 124.41
54.17
189.7
3-Year Revenue Growth Rate 21.60
BIIB's 3-Year Revenue Growth Rate is ranked higher than
75% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BIIB: 21.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.1  Med: 21.6 Max: 78.2
Current: 21.6
-15.1
78.2
3-Year EBITDA Growth Rate 28.10
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. BIIB: 28.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 28.1
0
127.9
3-Year EPS without NRI Growth Rate 29.40
BIIB's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. BIIB: 29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66  Med: 34.9 Max: 205.2
Current: 29.4
-66
205.2
GuruFocus has detected 2 Warning Signs with Biogen Inc $BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BIIB Guru Trades in Q3 2016

George Soros 1,994 sh (New)
Richard Pzena 642 sh (New)
Steven Cohen 117,548 sh (New)
Eric Mindich 64,000 sh (New)
Paul Tudor Jones 125,668 sh (+593.42%)
Jim Simons 238,261 sh (+489.75%)
John Paulson 308,000 sh (+150.20%)
First Eagle Investment 457,260 sh (+37.41%)
HOTCHKIS & WILEY 306,100 sh (+33.67%)
Jeff Auxier 22,635 sh (+25.85%)
David Dreman 150 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Paul Tudor Jones 20,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Ronald Muhlenkamp 23,478 sh (-0.95%)
John Buckingham 16,642 sh (-1.12%)
Ken Fisher 100,718 sh (-1.18%)
PRIMECAP Management 15,693,905 sh (-2.07%)
Richard Snow 203,525 sh (-3.80%)
Vanguard Health Care Fund 3,759,703 sh (-4.98%)
Lee Ainslie 10,380 sh (-5.72%)
Frank Sands 2,789,266 sh (-6.09%)
Sarah Ketterer 404,444 sh (-17.34%)
Andreas Halvorsen 2,186,336 sh (-31.90%)
Joel Greenblatt 245,468 sh (-33.31%)
Pioneer Investments 665 sh (-39.49%)
Mario Gabelli 1,897 sh (-60.45%)
Ron Baron 6,577 sh (-66.48%)
Ray Dalio 900 sh (-98.25%)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (-5.40%)
» More
Q4 2016

BIIB Guru Trades in Q4 2016

John Hussman 350 sh (New)
John Burbank 5,904 sh (New)
Eric Mindich 327,882 sh (+412.32%)
David Dreman 602 sh (+301.33%)
Jim Simons 707,495 sh (+196.94%)
Jeff Auxier 25,305 sh (+11.80%)
Lee Ainslie 10,880 sh (+4.82%)
Vanguard Health Care Fund 3,841,803 sh (+2.18%)
John Buckingham 16,934 sh (+1.75%)
Ken Fisher 101,887 sh (+1.16%)
Ron Baron 6,625 sh (+0.73%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Eric Mindich 400,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (unchged)
George Soros Sold Out
Richard Pzena Sold Out
Sarah Ketterer Sold Out
Pioneer Investments Sold Out
Ray Dalio Sold Out
PRIMECAP Management 15,584,387 sh (-0.70%)
Ronald Muhlenkamp 23,279 sh (-0.85%)
Mario Gabelli 1,872 sh (-1.32%)
Joel Greenblatt 240,311 sh (-2.10%)
Richard Snow 192,361 sh (-5.49%)
HOTCHKIS & WILEY 286,800 sh (-6.31%)
Frank Sands 2,578,909 sh (-7.54%)
Andreas Halvorsen 1,918,812 sh (-12.24%)
Murray Stahl 6,655 sh (-13.63%)
First Eagle Investment 257,025 sh (-43.79%)
Steven Cohen 53,542 sh (-54.45%)
John Paulson 52,200 sh (-83.05%)
Paul Tudor Jones 7,815 sh (-93.78%)
» More
Q1 2017

BIIB Guru Trades in Q1 2017

Leucadia National 1,716 sh (New)
Richard Pzena 759 sh (New)
Jeremy Grantham 1,480 sh (New)
Manning & Napier Advisors, Inc 122,675 sh (New)
Caxton Associates 1,200 sh (New)
Pioneer Investments 54,344 sh (New)
Ray Dalio 45,447 sh (New)
Steven Cohen 216,470 sh (+304.30%)
Jim Simons 848,961 sh (+20.00%)
Joel Greenblatt 275,460 sh (+14.63%)
Ronald Muhlenkamp 25,557 sh (+9.79%)
Ken Fisher 109,414 sh (+7.39%)
Jeff Auxier 25,875 sh (+2.25%)
John Buckingham 17,061 sh (+0.75%)
Vanguard Health Care Fund 3,841,803 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Ron Baron 6,625 sh (unchged)
First Eagle Investment 1,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
David Dreman Sold Out
First Eagle Investment Sold Out
HOTCHKIS & WILEY 286,572 sh (-0.08%)
PRIMECAP Management 15,477,424 sh (-0.69%)
Richard Snow 186,104 sh (-3.25%)
John Burbank 5,671 sh (-3.95%)
Frank Sands 2,475,937 sh (-3.99%)
Mario Gabelli 1,772 sh (-5.34%)
Lee Ainslie 9,610 sh (-11.67%)
John Hussman 250 sh (-28.57%)
Murray Stahl 4,645 sh (-30.20%)
Andreas Halvorsen 688,765 sh (-64.10%)
Eric Mindich 111,191 sh (-66.09%)
John Paulson 17,300 sh (-66.86%)
Paul Tudor Jones 1,752 sh (-77.58%)
Eaton Vance Worldwide Health Sciences Fund 154,569 sh (-7.17%)
» More
Q2 2017

BIIB Guru Trades in Q2 2017

David Dreman 3,705 sh (New)
John Hussman 10,000 sh (+3900.00%)
Jeremy Grantham 24,484 sh (+1554.32%)
Manning & Napier Advisors, Inc 814,369 sh (+563.84%)
Steven Cohen 892,101 sh (+312.11%)
Ron Baron 12,935 sh (+95.25%)
Lee Ainslie 15,230 sh (+58.48%)
Caxton Associates 1,500 sh (+25.00%)
Richard Snow 215,182 sh (+15.62%)
Jeff Auxier 28,170 sh (+8.87%)
Mairs and Power 1,053 sh (+2.73%)
HOTCHKIS & WILEY 286,572 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
Murray Stahl 4,645 sh (unchged)
Richard Pzena Sold Out
Leucadia National Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
John Paulson Sold Out
John Buckingham 17,055 sh (-0.04%)
Ronald Muhlenkamp 25,545 sh (-0.05%)
Ken Fisher 109,129 sh (-0.26%)
PRIMECAP Management 15,391,401 sh (-0.56%)
Ray Dalio 44,981 sh (-1.03%)
Mario Gabelli 1,750 sh (-1.24%)
Vanguard Health Care Fund 3,784,603 sh (-1.49%)
Jim Simons 762,861 sh (-10.14%)
Joel Greenblatt 162,464 sh (-41.02%)
Frank Sands 1,278,163 sh (-48.38%)
Pioneer Investments 26,290 sh (-51.62%)
Eaton Vance Worldwide Health Sciences Fund 132,800 sh (-14.08%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.03%$246.54 - $286.89 $ 281.777%3,784,603
Joel Greenblatt 2017-06-30 Reduce -41.02%0.39%$246.54 - $286.89 $ 281.777%162,464
Ken Fisher 2017-06-30 Reduce -0.26%$246.54 - $286.89 $ 281.777%109,129
Ronald Muhlenkamp 2017-06-30 Reduce -0.05%$246.54 - $286.89 $ 281.777%25,545
Ron Baron 2017-06-30 Add 95.25%0.01%$246.54 - $286.89 $ 281.777%12,935
David Dreman 2017-06-30 New Buy0.55%$246.54 - $286.89 $ 281.777%3,705
Mario Gabelli 2017-06-30 Reduce -1.24%$246.54 - $286.89 $ 281.777%1,750
Richard Pzena 2017-06-30 Sold Out $246.54 - $286.89 $ 281.777%0
Leucadia National 2017-06-30 Sold Out 0.04%$246.54 - $286.89 $ 281.777%0
John Paulson 2017-06-30 Sold Out 0.06%$246.54 - $286.89 $ 281.777%0
HOTCHKIS & WILEY 2017-03-31 Reduce -0.08%$251.68 - $297.85 $ 281.772%286,572
Joel Greenblatt 2017-03-31 Add 14.63%0.12%$251.68 - $297.85 $ 281.772%275,460
Ken Fisher 2017-03-31 Add 7.39%$251.68 - $297.85 $ 281.772%109,414
Ronald Muhlenkamp 2017-03-31 Add 9.79%0.19%$251.68 - $297.85 $ 281.772%25,557
John Paulson 2017-03-31 Reduce -66.86%0.11%$251.68 - $297.85 $ 281.772%17,300
Mario Gabelli 2017-03-31 Reduce -5.34%$251.68 - $297.85 $ 281.772%1,772
Leucadia National 2017-03-31 New Buy0.04%$251.68 - $297.85 $ 281.772%1,716
Richard Pzena 2017-03-31 New Buy$251.68 - $297.85 $ 281.772%759
First Eagle Investment 2017-03-31 Sold Out 0.17%$251.68 - $297.85 $ 281.772%0
David Dreman 2017-03-31 Sold Out 0.09%$251.68 - $297.85 $ 281.772%0
Vanguard Health Care Fund 2016-12-31 Add 2.18%0.06%$251.83 - $298.71 $ 281.773%3,841,803
HOTCHKIS & WILEY 2016-12-31 Reduce -6.31%0.03%$251.91 - $298.81 $ 281.773%286,800
First Eagle Investment 2016-12-31 Reduce -43.79%0.16%$251.91 - $298.81 $ 281.773%257,025
Joel Greenblatt 2016-12-31 Reduce -2.10%0.02%$251.91 - $298.81 $ 281.773%240,311
Ken Fisher 2016-12-31 Add 1.16%$251.83 - $298.71 $ 281.773%101,887
John Paulson 2016-12-31 Reduce -83.05%0.88%$251.91 - $298.81 $ 281.773%52,200
Ronald Muhlenkamp 2016-12-31 Reduce -0.85%0.02%$251.91 - $298.81 $ 281.773%23,279
Ron Baron 2016-12-31 Add 0.73%$251.91 - $298.81 $ 281.773%6,625
Mario Gabelli 2016-12-31 Reduce -1.32%$251.91 - $298.81 $ 281.773%1,872
David Dreman 2016-12-31 Add 301.33%0.07%$251.91 - $298.81 $ 281.773%602
George Soros 2016-12-31 Sold Out 0.02%$251.91 - $298.81 $ 281.773%0
Richard Pzena 2016-12-31 Sold Out $251.91 - $298.81 $ 281.773%0
Vanguard Health Care Fund 2016-09-30 Reduce -4.98%0.1%$222.86 - $303.97 $ 281.773%3,759,703
First Eagle Investment 2016-09-30 Add 37.41%0.1%$222.86 - $303.97 $ 281.773%457,260
John Paulson 2016-09-30 Add 150.20%0.64%$222.86 - $303.97 $ 281.773%308,000
HOTCHKIS & WILEY 2016-09-30 Add 33.67%0.1%$222.86 - $303.97 $ 281.773%306,100
Joel Greenblatt 2016-09-30 Reduce -33.31%0.36%$222.86 - $303.97 $ 281.773%245,468
Ken Fisher 2016-09-30 Reduce -1.18%$222.86 - $303.97 $ 281.773%100,718
Ronald Muhlenkamp 2016-09-30 Reduce -0.95%0.02%$222.86 - $303.97 $ 281.773%23,478
Ron Baron 2016-09-30 Reduce -66.48%0.02%$222.86 - $303.97 $ 281.773%6,577
George Soros 2016-09-30 New Buy0.02%$222.86 - $303.97 $ 281.773%1,994
Mario Gabelli 2016-09-30 Reduce -60.45%0.01%$222.86 - $303.97 $ 281.773%1,897
Richard Pzena 2016-09-30 New Buy$222.86 - $303.97 $ 281.773%642
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:GILD, NAS:CELG, NAS:BMRN, NAS:EXEL, NAS:ALNY, NAS:KITE, NAS:SGEN, NAS:BIVV, NAS:TSRO, NAS:IONS, NAS:UTHR, NAS:NBIX, NAS:TECH, NAS:BLUE, NAS:ACAD, NAS:CLVS » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and is launching Spinraza with partner Ionis.

Top Ranked Articles about Biogen Inc

AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies
Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies
Biogen Increases Revenue Guidance in 2nd Quarter Company reports solid revenue growth, completes agreement with Bristol-Myers Squibb
Biogen Inc. (NASDAQ:BIIB), a Cambridge, Massachusetts-based biotech company, reported continued success in its long-term company strategies during the quarter ending June 30. Read more...
Why GM, Caterpillar, McDonald's and Biogen Moved Higher Today The companies beat expectations
The corporate earnings season remains the center of attention for investors, though they will also keep an eye on the two-day meeting of the U.S. Federal Reserve that begins today. U.S. indexes were in the green in premarket trading on Tuesday as earnings reports for several companies were released.  Read more...
Jeff Ubben Buys 1, Sells 1 in 1st Quarter ValueAct leader to step down from CIO role
Jeff Ubben (Trades, Portfolio)’s ValueAct Holdings bought Bioverativ Inc. (NASDAQ:BIVV) and sold Allison Transmission Holdings Inc. (NYSE:ALSN) during the first quarter. Read more...
Ray Dalio Buys General Electric, Biogen, Walt Disney The guru's top 1st-quarter purchases
Ray Dalio (Trades, Portfolio) founded Greenwich, Connecticut-based hedge fund Bridgewater Associates in 1975. He manages a portfolio composed of 236 stocks with a total value of $8.818 billion. During the first quarter the guru bought shares in the following stocks: Read more...
BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience
Richard Pzena Invests in 3 Health Care Companies Guru releases 1st-quarter portfolio
Richard Pzena (Trades, Portfolio) gained 14 new holdings during the first quarter. Among them were three health care stocks, including Mylan NV(NASDAQ:MYL), Cardinal Health Inc. (NYSE:CAH) and Biogen Inc. (NASDAQ:BIIB). Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.48
BIIB's PE Ratio is ranked higher than
76% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BIIB: 18.48 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 21.59 Max: 100.96
Current: 18.48
10.8
100.96
Forward PE Ratio 13.21
BIIB's Forward PE Ratio is ranked higher than
77% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. BIIB: 13.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.48
BIIB's PE Ratio without NRI is ranked higher than
78% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. BIIB: 18.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 21.59 Max: 103.15
Current: 18.48
10.8
103.15
Price-to-Owner-Earnings 24.99
BIIB's Price-to-Owner-Earnings is ranked higher than
60% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. BIIB: 24.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.96  Med: 22.19 Max: 154.47
Current: 24.99
9.96
154.47
PB Ratio 5.14
BIIB's PB Ratio is ranked lower than
60% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BIIB: 5.14 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.22 Max: 8.84
Current: 5.14
1.71
8.84
PS Ratio 5.20
BIIB's PS Ratio is ranked higher than
70% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. BIIB: 5.20 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.34 Max: 10.99
Current: 5.2
2.58
10.99
Price-to-Free-Cash-Flow 29.55
BIIB's Price-to-Free-Cash-Flow is ranked higher than
51% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. BIIB: 29.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 19.33 Max: 36.13
Current: 29.55
9.25
36.13
Price-to-Operating-Cash-Flow 15.56
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. BIIB: 15.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.91 Max: 32.48
Current: 15.56
7.22
32.48
EV-to-EBIT 13.79
BIIB's EV-to-EBIT is ranked higher than
70% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. BIIB: 13.79 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14.7 Max: 37.8
Current: 13.79
7.5
37.8
EV-to-EBITDA 10.98
BIIB's EV-to-EBITDA is ranked higher than
72% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BIIB: 10.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.9 Max: 24.8
Current: 10.98
6.1
24.8
PEG Ratio 0.64
BIIB's PEG Ratio is ranked higher than
88% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. BIIB: 0.64 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.78 Max: 35.41
Current: 0.64
0.31
35.41
Shiller PE Ratio 32.79
BIIB's Shiller PE Ratio is ranked higher than
69% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. BIIB: 32.79 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.31  Med: 76.96 Max: 2372.5
Current: 32.79
29.31
2372.5
Current Ratio 2.10
BIIB's Current Ratio is ranked lower than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. BIIB: 2.10 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.16 Max: 20.41
Current: 2.1
0.78
20.41
Quick Ratio 1.83
BIIB's Quick Ratio is ranked lower than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. BIIB: 1.83 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.91 Max: 20.41
Current: 1.83
0.7
20.41
Days Inventory 229.73
BIIB's Days Inventory is ranked lower than
77% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. BIIB: 229.73 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 229.73
219.47
266.3
Days Sales Outstanding 50.78
BIIB's Days Sales Outstanding is ranked higher than
65% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. BIIB: 50.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 45.32 Max: 50.78
Current: 50.78
39.79
50.78
Days Payable 77.97
BIIB's Days Payable is ranked higher than
61% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. BIIB: 77.97 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 69.07  Med: 98.14 Max: 148.21
Current: 77.97
69.07
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BIIB: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: -0.3 Max: 30.9
Current: 3
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.26
BIIB's Price-to-Tangible-Book is ranked lower than
84% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BIIB: 16.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.07  Med: 4.87 Max: 24.42
Current: 16.26
0.07
24.42
Price-to-Intrinsic-Value-Projected-FCF 1.65
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. BIIB: 1.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.63 Max: 12.97
Current: 1.65
0.05
12.97
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.65
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
96% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. BIIB: 0.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.97
BIIB's Price-to-Median-PS-Value is ranked higher than
51% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BIIB: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.93 Max: 13.33
Current: 0.97
0.05
13.33
Price-to-Peter-Lynch-Fair-Value 0.74
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
93% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. BIIB: 0.74 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.15 Max: 18.88
Current: 0.74
0.41
18.88
Price-to-Graham-Number 3.66
BIIB's Price-to-Graham-Number is ranked lower than
60% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. BIIB: 3.66 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.07  Med: 2.82 Max: 33.65
Current: 3.66
0.07
33.65
Earnings Yield (Greenblatt) % 7.25
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. BIIB: 7.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 6.8 Max: 13.4
Current: 7.25
2.6
13.4
Forward Rate of Return (Yacktman) % 32.99
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
83% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. BIIB: 32.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.3  Med: 29.7 Max: 45.7
Current: 32.99
-1.3
45.7

More Statistics

Revenue (TTM) (Mil) $11,716.90
EPS (TTM) $ 15.25
Beta0.53
Short Percentage of Float1.45%
52-Week Range $244.28 - 303.81
Shares Outstanding (Mil)211.43

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11,792 12,160 12,526
EPS ($) 21.08 22.54 23.24
EPS without NRI ($) 21.08 22.54 23.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.64%
Dividends per Share ($)
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa C Aug 10 2017 
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigment Aug 03 2017 
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies Jul 28 2017 
Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies Jul 27 2017 
Biogen Increases Revenue Guidance in 2nd Quarter Jul 25 2017 
Why GM, Caterpillar, McDonald's and Biogen Moved Higher Today Jul 25 2017 
The 30 Best-Performing Stocks Since 1980 Jul 07 2017 
Seeking Value in Biotech: Bioverativ Jun 29 2017 
Seeking Value in Biotech: Biogen Jun 22 2017 
Jeff Ubben Buys 1, Sells 1 in 1st Quarter May 24 2017 

More From Other Websites
[$$] Biogen Treads Tricky Path Between Politicians, Investors Aug 18 2017
What's Up With Biogen? Aug 17 2017
Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation Aug 17 2017
See what the IHS Markit Score report has to say about Biogen Inc. Aug 17 2017
Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock Aug 16 2017
​Biogen gains $1B in value after Goldman Sachs touts Alzheimer’s drug Aug 16 2017
Goldman has a new favorite biotech because of potential A... Aug 16 2017
Biogen: Goldman Has Conviction! Aug 16 2017
Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List Aug 16 2017
Goldman has a new favorite biotech because of potential Alzheimer's blockbuster Aug 16 2017
Goldman Sachs adds Biogen to its Americas Conviction List Aug 16 2017
Pfizer’s Declining-Revenue Products in 2Q17 Aug 15 2017
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some... Aug 11 2017
IHS Markit Score downgrades Biogen Inc to 60 out of 100, ranking positively in only one out of three... Aug 10 2017
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa... Aug 10 2017
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix Aug 09 2017
Top Analyst Reports for Biogen, Activision & Cigna Aug 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}